| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3)：209-249.
|
| [2] |
中国乳腺癌新辅助治疗专家共识专家组．中国乳腺癌新辅助治疗专家共识(2022年版)[J].中国癌症杂志，2022，32(1)：80-89.
|
| [3] |
Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER-2-positive locally advanced breast cancer (the NOAH trial)：randomised controlled superiority trial with a parallel HER-2-negative cohort[J]. Lancet，2010，375(9712)：377-384.
|
| [4] |
Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER-2-positive breast cancer(NeoSphere)：a randomised multicentre, open-label, phase 2 trial[J]. Lancet Oncol，2012，13(1)：25-32.
|
| [5] |
Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER-2-positive breastcancer (KRISTINE)：a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Oncol，2018，19(1)：115-126.
|
| [6] |
Van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER-2 blockade for HER-2-positive breast cancer (TRAIN-2)：a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol，2018，19(12)：1630-1640.
|
| [7] |
Swain SM, Ewer MS, Viale G, et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER-2-positive localized breast cancer (BERENICE)：a phase II, open-label, multicenter, multinational cardiac safety study[J]. Ann Oncol.2018，29(3)：646-653.
|
| [8] |
Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER-2-positive early breast cancer(TRYPHAENA): a randomized phase II cardiac safety study[J]. Ann Oncol，2013，24(9)：2278-2284.
|
| [9] |
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer：the CTNeoBC pooled analysis[J]. Lancet，2014，384(9938): 164-172.
|
| [10] |
Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer：ASCO guideline[J]. J Clin Oncol，2021，39(13)：1485-1505.
|
| [11] |
Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer：ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2019, 30(8)：1194-1220.
|
| [12] |
中国抗癌协会乳腺癌专业委员会，中华医学会肿瘤学分会乳腺肿瘤学组．中国抗癌协会乳腺癌诊治指南与规范(2024年版)[J].中国癌症杂志，2023，33(12): 1092-1186.
|
| [13] |
NCCN Clinical Practice Guidelines in Oncology－Breat Cancer(version 4.2023)[EB/OL].[2024-01-13].
URL
|
| [14] |
中国临床肿瘤学会指南工作委员会．中国临床肿瘤学会乳腺癌(CSCO BC)诊疗指南2023.[M].北京：人民卫生出版社，2023：29-34.
|
| [15] |
Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER-2-positive breast cancer (NeoSphere)：a multicentre, open-label, phase 2 randomised trial[J]. Lancet Oncol，2016，17(6)：791-800.
|
| [16] |
Shao Z, Pang D, Yang H, et al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia：The PEONY Phase 3 Randomized Clinical Trial[J]. JAMA Oncol，2020，6(3)：e193692.
|
| [17] |
Shao Z, Pang D, Yang H, et al. Final analysis of the phase III PEONY trial：long-term efficacy and safety of neoadjuvant-adjuvant pertuzumab or placebo, plus trastuzumab and docetaxel, in patients with HER-2-positive early or locally advanced breast cancer[J]. Cancer Res，2023，83(5 Suppl): PD18-03.
|
| [18] |
Nitz U, Gluz O, Graeser M, et al. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER-2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER-2＋/HR-)：survival outcomes from a multicentre, open-label, randomised, phase 2 trial[J]. Lancet Oncol，2022，23(5)：625-635.
|
| [19] |
Gluz, O, Ulrike N, Christgen M，et al. De-escalated chemotherapy versus endocrine therapy plus pertuzumab＋ trastuzumab for HR＋/HER-2＋ early breast cancer (BC): first efficacy results from the neoadjuvant WSG-TP-II study[J]. Clin Oncol，2020，38：515.
|
| [20] |
Sayeh M, Lavasani, George Somlo, et al. Phase 2 prospective open label study of neoadjuvant nab‐paclitaxel, trastuzumab, and pertuzumab in patients with HER-2‐positive primary breast cancer[J]. Cancer，2023，129(5)：740-749.
|
| [21] |
Hatschek T, Foukakis T, Bjöhle J, et al. Neoadjuvant rastuzumab, pertuzumab, and docetaxel vs trastuzumab emtansine in patients with ERBB2-Positive breast cancer: phase 2 randomized clinical trial[J]. JAMA Oncol，2021，7(9)：1360-1367.
|
| [22] |
Matikas A, Johansson H, Grybäck P, et al. Survival outcomes, digital TILs, and on-treatment PET/CT during neoadjuvant therapy for HER-2-positive breast cancer：results from the randomized PREDIX HER-2 trial[J]. Clin Cancer Res，2023，29(3)：532-540.
|
| [23] |
中国临床肿瘤学会乳腺癌专家委员会，中国抗癌协会乳腺癌专业委员会．人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识(2021版)[J].中华医学杂志，2021，101(17): 1226-1231.
|
| [24] |
Cheng Y, Xiang H, Xin L，et al. Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China：a multicenter real-world study (CSBrS-015)[J]. Chin Med J，2022，135：2311-2318.
|
| [25] |
岳瑞雪，胡崇珠，郝鑫等．曲妥珠单克隆抗体和帕妥珠单克隆抗体联合不同化疗方案新辅助治疗HER-2阳性乳腺癌真实世界疗效及安全性观察[J].中国肿瘤临床，2023，50(5)：248-254.
|
| [26] |
Zhou M, Wang S, Wan N, et al. Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER-2-positive early breast cancer：a real-world retrospective multi-center cohort study[J]. Ann Transl Med，2022，10(24)：1387.
|
| [27] |
González-Santiago S, Saura C, Ciruelos E, et al. Real-world effectiveness of dual HER-2 blockade with per-tuzumab and trastuzumab for neoadjuvant treatment of HER-2-positive early breast cancer (the NEOPETRA study)[J]. Breast Cancer Res Treat，2020，184(2)：469-479.
|
| [28] |
Medina EAG, Caballero BB, iguel KL, et al. Neoadjuvant trastuzumab and pertuzumab in combination with standard chemotherapy for HER-2-positive early breast cancer：real-world practice in Cuba[J]. Cancer Treat Res Commun，2023，34：100670.
|
| [29] |
Lv M, Guo H, Wang C，et al. Neoadjuvant docetaxel with or without carboplatin plus dual HER-2 blockade for HER-2-positive breast cancer：a retrospective multicenter Chinese study[J]. Gland Surg，2020，9(6)：2079-2090.
|
| [30] |
Liu ZZ, Chen XC, Qiao JH, et al. De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab in HER-2-positive early breast cancer (HELEN-006)：a randomized, phase 3 trial[EB/OL].[2024-01-20].
URL
|